Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition

NCT05657691 is registered in ClinicalTrials.gov with Actinogen Medical as lead sponsor.

NCT NCT05657691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05657691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition
Lead sponsor
Actinogen Medical
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2022
Completion date
July 1, 2024
Enrollment
167 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, major depressive disorder, mdd